Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: Experience from Japanese clinical trials

Modern Rheumatology

Volumn 21, Issue 6, 2011, Pages 572-578

  Mori, Masaaki ^a,d   Takei, Syuji ^b   Imagawa, Tomoyuki ^a   Imanaka, Hiroyuki ^b   Nerome, Yasuhito ^b   Kurosawa, Rumiko ^a   Kawano, Yoshifumi ^b   Yokota, Shumpei ^a   Sugiyama, Noriko ^c   Yuasa, Hirotoshi ^c   Fletcher, Tracey ^c   Wajdula, Joseph S ^c  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c PFIZER INC   (United States)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Children; Clinical trial; Etanercept; Juvenile idiopathic arthritis; Polyarticular course

Indexed keywords

ACTARIT; AUROTHIOMALATE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGY; APPENDICITIS; APPLICATION SITE EXCORIATION; ARTHROPOD DISEASE; ARTICLE; CELLULITIS; CHILD; CLINICAL ARTICLE; CONTUSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; EPISTAXIS; ERYTHEMA; FEMALE; FEVER; GASTROENTERITIS; GENERAL CONDITION DETERIORATION; HEADACHE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPETIGO; INFECTION; INFLUENZA; INGUINAL HERNIA; INJECTION SITE BLEEDING; INJECTION SITE REACTION; JAPAN; JOINT CONTRACTURE; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MYALGIA; MYCOPLASMA PNEUMONIA; NOSE CONGESTION; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; STOMATITIS; SUBCUTANEOUS HEMORRHAGE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; UVEITIS; VOMITING;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; JAPAN; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84855683647     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0450-7     Document Type: Article

References (14)

1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-2. (Pubitemid 38160763)
2. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15-25.
3. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342(11):763-9. (Pubitemid 30151920)
4. Prince FH, Twilt M, Jansen-Wijngaarden NC, van Suijlekom- Smit LW. Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: A clinical study. Ann Rheum Dis. 2007;66(5):704-5. (Pubitemid 46707146)
5. Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol. 2004;31(10): 2055-61. (Pubitemid 39336735)
6. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: An open label study. Ann Rheum Dis. 2003;62(3):245-7. (Pubitemid 36238089)
7. Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: The Dutch national register. Ann Rheum Dis. 2009;68(5):635-41.
8. Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006;54(6):1987-94. (Pubitemid 43877949)
9. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496-504. (Pubitemid 351705939)
10. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003;48(1):218-26. (Pubitemid 36091666)
11. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(9):2794-804.
12. Brewer EJ Jr, Bass J, Baum J, Cassidy JT, Fink C, Jacobs J, et al. Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation. Arthritis Rheum. 1977;20(2 Suppl):195-9.
13. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202-9. (Pubitemid 27430130)
14. Mori M, Naruto T, Imagawa T, Murata T, Takei S, Tomiita M, et al. Methotrexate for the treatment of juvenile idiopathic arthritis: Process to approval for JIA indication in Japan. Mod Rheumatol. 2009;19(1):1-11.